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Label-free plasma proteomics 
identifies haptoglobin-related 
protein as candidate marker of 
idiopathic pulmonary fibrosis and 
dysregulation of complement and 
oxidative pathways
Mayank Saraswat1,2,5,6,7 ✉, Sakari Joenväärä1,2, Tiialotta Tohmola1,2, Eva Sutinen3,4, 
Ville Vartiainen3,4, Katri Koli4, Marjukka Myllärniemi3,4 & Risto Renkonen1,2
Idiopathic pulmonary fibrosis (IPF) is a lung parenchymal disease of unknown cause usually occurring 
in older adults. It is a chronic and progressive condition with poor prognosis and diagnosis is largely 
clinical. Currently, there exist few biomarkers that can predict patient outcome or response to 
therapies. Together with lack of markers, the need for novel markers for the detection and monitoring 
of IPF, is paramount. We have performed label-free plasma proteomics of thirty six individuals, 17 
of which had confirmed IPF. Proteomics data was analyzed by volcano plot, hierarchical clustering, 
Partial-least square discriminant analysis (PLS-DA) and Ingenuity pathway analysis. Univariate and 
multivariate statistical analysis overlap identified haptoglobin-related protein as a possible marker of 
IPF when compared to control samples (Area under the curve 0.851, ROC-analysis). LXR/RXR activation 
and complement activation pathways were enriched in t-test significant proteins and oxidative 
regulators, complement proteins and protease inhibitors were enriched in PLS-DA significant proteins. 
Our pilot study points towards aberrations in complement activation and oxidative damage in IPF 
patients and provides haptoglobin-related protein as a new candidate biomarker of IPF.
Idiopathic pulmonary fibrosis is chronic, progressive, interstitial pneumonia of unknown cause usually occurring 
in older adults and presents with usual interstitial pneumonia (UIP) in histopathological and/or radiological 
findings. Current data suggests that the incidence of IPF has been increasing in some parts of the world includ-
ing Europe1. The diagnosis of IPF is largely clinical and radiological and laboratory investigations are often not 
helpful although they can be used to rule out other conditions. The common symptoms include breathlessness 
on exertion, decreasing pulmonary function, bibasilar inspiratory crackles and finger clubbing in 50% of the 
patients2–4. Decline in respiratory function can be slow and progressive or rapid and accelerated giving rise to 
variable survival pattern. Damage in IPF is usually irreversible and unpredictable and prognosis is extremely 
poor2–4. According to collaborative efforts of the American Thoracic Society, the European Respiratory Society, 
the Japanese Respiratory Society, and the Latin American Thoracic Association, diagnosis requires exclusion of 
other known causes of interstitial lung disease (environmental exposure, drug toxicities and connective tissue 
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disease), presence of a UIP pattern on high-resolution computed tomography (HRCT) and/or combination of 
UIP pattern in HRCT and surgical lung biopsies2.
IPF can lead to the death of patients in 3–5 years after onset of symptoms2. Options for therapy of IPF are 
controversial due to lack of knowledge of common suitable symptoms for initiating therapy and until a few years 
ago, lung transplant was the only option. Two antifibrotic agents have been approved by the FDA and EMA. There 
exists a lack of understanding of molecular mechanisms driving the disease as well as suitable detection and mon-
itoring biomarkers. Larger efforts are needed to find suitable minimally invasive biomarkers of the IPF to help 
early diagnosis and therapy onset.
We have performed label-free plasma proteomics on 36 plasma samples including 17 confirmed IPF cases 
(2011 ATS/ERS/JRS/ALAT diagnostic guidelines2) and 19 healthy controls. The sample collection was done 
in accordance with 2011 ATS/ERS/JRS/ALAT guidelines. Since then, 2018 guidelines have become available5 
however the major diagnostic criterion remains unchanged. We have quantified 167 proteins with 2 or more 
unique peptides out of which 74 were significantly different between the IPF and controls by t-test. FDR cor-
rection reduced this number to 66. Multivariate statistical analysis methods were employed to find suitable 
high-confidence biomarkers. Their performance was evaluated by ROC curve analysis.
Results
Metadata. Detailed patient characteristics (including measurements of lung function tests of IPF cases) for 
the study population are given in Supplementary Table 1 in Supplementary dataset. Nineteen healthy individuals 
(5 females, 14 males) and 17 IPF cases (3 females and 14 males) comprise the study population. The median age 
for the healthy group was 73 years and 71 years for IPF cases. The current study is designed according to a binary 
case-control comparison.
Label-free Proteomics and differential proteins. Hundred and sixty six proteins were quantified with 
2 or more unique peptides. Total peptides identified included 5416 out of which 4261 were unique to various 
proteins (Supplementary table 2 in Supplementary dataset). Confidence score ranged from 6.4 for carbonic anhy-
drase 1 to 3093 for complement C3. Levels of Seventy four proteins were significantly different between the 
groups (IPF vs controls, t-test p value <0.05, Supplementary table 2 in Supplementary dataset) out of which 10 
had a highest mean in IPF and 64 had highest mean in controls. The median power to separate the groups was 
0.908 among these proteins. Benjamini-Hochberg FDR correction was applied to the dataset and 66 proteins were 
differentially expressed between the groups (FDR corrected p value <0.05, Supplementary Table 2). Ten out of 
these 66 proteins had increased amounts in IPF patients and 56 others had increased amounts in controls.
Further statistical analysis. Hierarchical clustering was performed for all proteins (Supplementary Figure 
1) as well as differentially expressed proteins (FDR corrected p value <0.05, Fig. 1) to test if the groups can be 
separated by unsupervised statistical techniques. Clustering the groups by all proteins produced mixed groups 
(Supplementary Figure 1) which can be expected with majority of the proteins being non-differing between the 
groups. When significantly differing proteins were used for clustering the sample groups there was good separa-
tion between IPF and controls however few samples overlapped into each other’s group (Fig. 1). To tease out the 
natural contrast in protein expression between the groups, clustering was also performed by forcing the samples 
in each group to be organized together utilizing 66 differentially expressed proteins (Supplementary Figure 2). 
Here, 10 proteins increased in IPF patients and 56 in controls could be clearly seen to have a contrasting pattern.
Encouraged by clustering, we performed partial least square-discriminant analysis modeling on pareto-scaled 
data to find out the separation between IPF and controls and simultaneously identify the proteins whose expres-
sion can separate the 2 groups. All 166 proteins were used for PLS-DA modeling and scores plot was generated 
(Fig. 2). The scores plot showed separation between the two groups based on their expression (Fig. 2). However 
score plot cannot be used to gauge the separation of groups on face value because of the common problem of 
overfitting of the model6. Ten-fold cross validation was employed to test the fit (R2), accuracy and predictive abil-
ity (Q2) which can be seen in the Supplementary Figure 3. Ten fold CV produced reasonably good model param-
eters with very significant predictive accuracy (Q2) which was highest with top 4 components (latent variables).
Selection of biomarkers. Candidate biomarker selection was carried out in two steps; coarse selection 
and fine selection. Coarse selection involved volcano plot and VIP values generated by PLS-DA modeling and 
fine selection was done by finding significant proteins which overlap between these 2 techniques. As a last step, 
Receiver operating characteristic curve analysis was employed to calculate the area under the curve values.
Coarse selection. For selecting biomarker candidates, a volcano plot was generated by putting negative log-
arithm of the FDR corrected p value on Y axis and Log2 fold change on X axis (Fig. 3). Proteins having FDR cor-
rected p value of less than 0.05 (Horizontal red dashed line, Fig. 3) and fold change of at least 2 (2 Vertical dashed 
lines, Fig. 3) were selected in the first step of coarse selection. Seven proteins passing these criteria are described 
in Table 1.
Going back to the PLS-DA model, the most significant top protein features able to classify the 2 group 
of samples were selected based on variable influence on projections (VIP) values (Supplementary Table 2 
in Supplementary dataset). Proteins having VIP value of 1 or higher were considered the best classifiers 
(Supplementary Table 2 in Supplementary dataset). Thirty proteins had a VIP value of 1 or more, but as a cross 
validation, only the proteins which were significant by FDR corrected p value proteins list and also having VIP 
value of more than 1 were considered leaving us with 24 proteins (Supplementary Table 2 in Supplementary data-
set). These proteins are called “top significant in PLS-DA modeling” here onwards. Complement C3, Testis- and 
ovary-specific PAZ domain-containing protein 1 (TOPAZ1) and hemopexin among others came out as the most 
important features to classify the IPF vs controls groups.
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Fine selection. To finally select candidate biomarkers able to classify the IPF patients from healthy controls, 
proteins overlapping between the FDR significant proteins and PLS-DA VIP list were selected. An additional filter 
was applied and proteins were required to have a fold change of at least two. Comparing volcano plot significant 
proteins and proteins selected by VIP method gave us only one protein as a strong marker, Haptoglobin-related 
protein. This protein was reduced 2.2 times in IPF patients plasma compared to healthy controls. It was identified 
with 5 unique peptides with confidence score of 365.71 with power of 0.99 to separate the groups. As a last step, 
ROC curve analysis was performed and area under the curve (AUC) value of 0.851 was found (Fig. 4). At cutoff 
of normalized abundance value of 75400, it had 80% sensitivity and 80% selectivity.
Pathway analysis. Ingenuity pathway analysis was used for performing “Core analysis” on IPF vs Controls 
proteomics dataset. It gave several enriched canonical pathways (B-H p-values <0.05) in the dataset (Fig. 5) 
including LXR/RXR/FXR activation, acute phase response signaling, complement system and coagulation system 
among others. Remember that in top proteins selected by VIP values in PLS-DA modeling there were several 
complement proteins and coagulation regulators (Supplementary Table 2 in Supplementary Dataset). These pro-
teins were also significant by FDR corrected t-test p values in IPF vs Controls.
Discussion
2011 diagnostic guidelines of ATS/ERS/JRS/ALAT require a largely clinical and radiological diagnosis of IPF. The 
median time for diagnosis of IPF from symptom onset is 12 months (data for North America) and a quarter of 
the patients are not diagnosed for up to 26 months7. This is unfortunate as the median survival time of patients 
with IPF ranges from 30–42 months8,9. Not many treatment options remain at advanced stage of the disease and 
access to lung transplantation within reasonable time varies according to geographical location among other 
factors. There is a very strong need for IPF detection and monitoring biomarkers to make further improvements 
Figure 1. Hierarchical Clustering heatmap. Hierarchical clustering was performed for Controls and Idiopathic 
pulmonary fibrosis (IPF) comparison considering sixty two Benjamini-Hochberg FDR corrected t-test p value 
(<0.05) passing proteins. Metaboanalyst 4.0 was used for performing the clustering. Horizontal axis is all 
the samples analyzed in the study and vertical axis denotes Uniprot accessions for 66 proteins. On top of the 
heatmap are controls samples in green squares and IPF samples (Cases) in red squares. Dendrogram for samples 
is shown on top of the heatmap and proteins’ dendrogram on left side of the heatmap. Dark blue to dark red 
colour gradient denotes lower to higher expression.
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Figure 2. Scores plot for Partial least square-discriminant analysis. Score plot shows Idiopathic pulmonary 
fibrosis (IPF) in red and controls in green circles. A five component modeling was performed by PLS-DA using 
MetaboAnalyst 4.0 program. Ovals show 95% confidence interval for both IPF (red oval) and controls (green 
oval). This is a scatter plot for 2 components having the greatest variations. Observations that are similar will 
fall close to each other displaying a clustering-like pattern. Component 1 (X-axis) contains 40.8% of the total 
variation and component 2 contains 12.2%. Plotting the scores will display separation of the samples in a score 
plot, as shown.
Figure 3. Volcano Plot. X-axis is the Log2 of linear fold change (IPF/Controls) and Y-axis is the negative Log10 
of the Benjamini-Hochberg corrected t-test p value. Vertical red dashed lines denote a linear fold change of 2 in 
either direction (IPF/Controls or Controls/IPF). Horizontal red dashed line denotes a cutoff of 0.05 for the FDR 
corrected p value. Any protein which falls to the left or right of vertical red dashed lines and above horizontal 
red dashed line (p value <0.05) is deemed to be significant different between the groups.
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in treatment of the disease. Additionally, identification of dysregulated systemic pathways will also help further 
the understanding of the disease and provide avenues for further research into diagnosis and treatment. We have 
performed label-free plasma proteomics in 37 individuals including 17 confirmed cases of IPF and 20 healthy 
controls with the aim of finding novel markers of the disease.
Hierarchical clustering provided good separation of the IPF vs control samples which only improved when 
differentially expressed proteins’ data was employed, as can be expected in case of true differential expression. 
Further, PLS-DA was performed after pareto scaling of the data. In OMICS data, variable usually have very differ-
ent ranges which creates sub-optimal modeling and interpretation of such analysis is difficult. Variable are trans-
formed by scaling to circumvent this problem. Pareto scaling is normally used in multivariate data analysis10,11 
to upscale the medium features without increasing baseline noise unlike unit variance (UV) scaling. PLS-DA is 
sensitive to scaling and different features having impact on separation and the real separation itself can be more 
easily revealed on scaled data10. It is to be noted that large values receive more attention in pareto scaling but it 
is beneficial in analysis of proteomics data and increases confidence in results as larger peaks will have better 
signal/noise ratio compared to peaks close to background. In a clinical proteomics study, biomarker selection is 
often the goal and precision, predictive ability, sensitivity and selectivity are of obvious importance. In a binary 
comparison, there are a number of univariate and multivariate feature selection methods available to scientists. 
However, large systematic studies where these feature selection methods have been compared to each other in 
terms of their performance are lacking. Together with varying degree of statistical know-how in biomedical scien-
tists, it leads to a situation where there are no consensus guidelines as to what method should be used in any given 
Accession Description
FDR corrected 
p-values
Peptide 
count
Unique 
peptides
Confidence 
score
Fold 
change Power
Highest 
mean
Lowest 
mean
P00739 Haptoglobin-related protein 0.005030 27 5 365.7 2.19 0.990 CONTROL CASE
P22352 Glutathione peroxidase 3 0.000454 8 6 60.7 2.76 0.999 CONTROL CASE
O43866 CD5 antigen-like 0.000454 5 5 33.5 2.28 0.999 CONTROL CASE
P48426 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 0.003576 4 2 18.5 3.35 0.993 CASE CONTROL
P0C0L5 Complement C4-B 0.020712 161 6 1863.9 2.48 0.857 CONTROL CASE
Q96IY4 Carboxypeptidase B2 0.023661 6 3 43.3 2.51 0.995 CONTROL CASE
Q8N1N0 C-type lectin domain family 4 member F 0.02245 3 2 21.5 2.58 0.974 CONTROL CASE
Table 1. Volcano plot significant proteins are shown in the table. These proteins passed the cutoff of having less 
than 0.05 of FDR corrected t-test p value and having a linear fold change of at least two in either direction, either 
higher in Idiopathic pulmonary fibrosis (Case) or controls. Uniprot accession, protein name (Description), 
Benjamini-Hochberg false discovery rate corrected p-values, total peptide count, unique peptides unique to 
the given protein, confidence score of identification, fold Changes and highest mean conditions are given in the 
table.
Figure 4. Receiver operating characteristics curve analysis of Haptoglobin-related protein to differentiate 
idiopathic pulmonary fibrosis (IPF) from controls. Sensitivity (Y-axis) is plotted against 1-specificity for 
haptoglobin-related protein (Uniprot Accession: P00739) to differentiate between IPF and controls. Area 
under the curve value is shown on the ROC curve together with 95% confidence interval. At cutoff of 75400 
(normalized abundance level), 80% of sensitivity and 80% of specificity was achieved. At right side of ROC 
curve, a box plot is shown to compare the two groups with individual samples shown as empty circles for cases 
(IPF) and black filled circles for controls.
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situation. It has been shown that when sample size reach n = 15 per group, t-test combined with FDR correction 
is the best performing (precision, true positives) method  compared to nearest shrunken centroid, support vector 
machine, principal component discriminant analysis and PLS-DA12. Of note, large within class variance and low 
sample size (n ≤ 6) leads to poor t-test performance in selecting the best discriminating features12. Same study 
found that PLS-DA is largely unaffected by low sample size or between- and within-class variability. Combining 
the strength of both of these methods, we employed coarse selection of biomarkers using FDR corrected t-test 
p values (additionally requiring FC ≥ 2) and PLS-DA significant proteins (VIP ≥ 1). In current study, PLS-DA 
provided  30 proteins with VIP values of more than one, 24 of which (Supplementary Table 2 in Supplementary 
dataset) were also significant by FDR corrected t-test p value (<0.05). A volcano plot was generated by plotting 
FDR corrected t-test p values and fold change. Seven significant proteins were found having fold change of more 
than two (Table 1). In the fine selection of biomarkers, proteins overlapping between the volcano plot significant 
and VIP ( ≥ 1) significant were proposed as candidate biomarkers. This provided HPR as the only biomarker 
candidate. Three pertinent themes are sequentially discussed in this section namely; Volcano plot significant 
proteins, PLS-DA significant proteins and pathways and HPR as proposed candidate biomarker to discriminate 
IPF from healthy individuals.
Volcano Plot significant proteins included Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 
(PIP4K2A), which was 3.35 fold increased in plasma of IPF patients. There are no reports linking PIP4K2A to 
IPF or fibrosis in general however, lipid species phosphatidylinositol 5-phosphate acts as a second messenger and 
elicits innate antiviral response13. PIP4K2A converts Phosphatidylinositol 5-phosphate to phosphatidylinositol 
4,5-bisphosphate regulating its levels which might lead to diminished innate immunity. In line with this hypoth-
esis, sustained induction of innate immunity is known to amplify fibrosis by several mechanisms14. Six other vol-
cano plot significant proteins had reduced levels in IPF patients’ plasma including Complement C4B, Glutathione 
peroxidase 3 (GPx3), Haptoglobin related protein (HPR), CD5 antigen-like (CD5L) and Carboxypeptidase B2 
(CPB2). Of note, several proteases in our dataset had significantly reduced expression in IPF plasma including 
Carboxypeptidase N. Glutathione peroxidase 1 (GPx1) works downstream of Nrf2/Bach1, a major intracellular 
antioxidant effector axis. It has been shown that perfenidone treatment inhibits Bach1 and improves GPx1 levels 
in bleomycin-induced pulmonary fibrosis15. GPx3 is a secreted antioxidant plasma counterpart of GPx1 and 
GPx2. It works in detoxification of reactive oxygen species by glutathione. We found 2.76 times reduced levels of 
GPx3 in IPF patients compared to healthy controls.
Some studies on serum and bronchoalveolar lavage fluid (BALF) have been previously performed to find the 
differentially expressed proteins in IPF patients16–19. Out of these seven proteins found significant by volcano 
plot criteria, putting them in context of published literature revealed that CPB2 and HPR have been previously 
detected to be reduced in IPF patients’16. Five other proteins found significant by volcano plot are novel to our 
study. CPB2 in the said study16 was found to have 1.24, 1.87 and 2.14 times higher levels in serum of controls 
compared to IPF patients in three different comparisons compared to FC of 2.45 in our study. Directionality and 
magnitude of change was comparable to our study and the slight difference could be related to the use of serum 
vs plasma. HPR, although found to be different (FC 2.65–4.2 CTRL/IPF) in the same study was not proposed as a 
potential specific biomarker. However, we found it to be the best performing biomarker by a number of statistical 
techniques. The other serum study17 using iTRAQ found 97 differentially expressed proteins and four were vali-
dated which did not include our panel of 7 potential biomarker proteins. This study did not provide enough infor-
mation to evaluate our proteins in comparison to their dataset. Additionally, two studies have been performed on 
BALF of IPF patients18,19, one of which compared familial vs sporadic cases of IPF18. Among the proteins quanti-
tatively analyzed by this study ceruloplasmin had a fold change of 5.6 between familial vs sporadic IPF patients. 
Figure 5. Canonical pathways. Bar chart showing significant canonical pathways (B-H p-value <0.05) 
generated by Ingenuity Pathway Analysis software “Core analysis” of significantly different proteins between 
Idiopathic pulmonary fibrosis and controls obtained using FDR corrected t-test (<0.05). “Data were analyzed 
through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-
analysis)”.
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Our study had a CV of 27.4% for this protein in the IPF group suggesting the discrepancies might be caused by 
two-dimensional electrophoresis vs shotgun proteomics comparison. Similarly other BALF study was also done 
with 2-DE based proteomics and did not have proteins common with our study’s differentially expressed proteins. 
We analyzed a recent large plasma proteomic dataset published by Bruederer et al.20 the inter-individual CV, for 
healthy individuals followed for weight loss and maintenance, was found to be 38%. Specifically for HPR the CV 
was 36.1% (1466 plasma samples from 433 individuals) and fold changes between baseline, 8 weeks of weight 
loss and 10 months of weight maintenance were 0.97 to 1.14. This further shows that on large population scale, 
having fold changes of 2 or more and CV of 36% with tightly controlled expression levels in larger cohort healthy 
population make HPR an attractive biomarker candidate for IPF. Despite lack of complete comparability due to 
different technical, instrument and cohort differences, it can be concluded that HPR in healthy individuals shows 
tight distribution. For the same reason our results need to be validated in larger international cohorts to establish 
the promise of HPR as a biomarker of IPF.
The top proteins significant in PLS-DA modeling can be divided into roughly three categories namely 
complement proteins, oxidation related proteins and protease inhibitors. Complement system has been sug-
gested to play a role in development and progression of IPF which was inferred from early studies detecting 
complement-activating immune complexes and fragments of activated complement proteins in serum and bron-
choalveolar lavage fluid of patients with pulmonary fibrosis21–24. The common gain-of-function MUC5B pro-
moter variant (rs35705950) is a strong risk factor for development of pulmonary fibrosis25. Both complement 
system and MUC5B are implicated in host defense and this MUC5B variant is associated with higher C3 gene 
expression in lung tissue further indicating role of complement system in pulmonary fibrosis progression25. In 
our study, C3 was lower in IPF patients than healthy controls, which points towards consumption of this protein 
in lung tissues in patients with IPF. Lower C3 levels in IPF patients blood compared to healthy controls has been 
previously reported26 supporting our findings. C1q, C1s, C2, C4B, C5, C6 and C8 were also significantly lower in 
IPF patients compared to healthy controls. Another molecule which regulates alternative complement pathway, 
complement factor H (CFH), was found to be downregulated in IPF patients in our study. Plasma protease C1 
inhibitor was also lower in IPF patients suggesting consumption in response to increased complement activation 
in IPF. This has been found in another study previously26. Whether, in response to putative higher complement 
activation in IPF lungs, host defense regulatory molecules (such as CFH) are consumed or they are inherently 
present in less amounts in IPF patients, that drives accelerated complement activation, remains to be established. 
Role of complement activation in IPF is an interesting and important area to study further.
Second class of proteins, which were present in significant proteins of PLS-DA, which could classify IPF from 
healthy controls was metal binding proteins/antioxidants which included hemopexin, ceruloplasmin and copper 
homeostasis protein cutC homolog. Hemopexin is an antioxidant transporter/enzyme which protects the body 
from oxidative damage of free heme27. Ceruloplasmin is a metal binding protein which transports and regulates 
the availability of copper in human plasma28. cutC is another copper transporter which transports the Cu to the 
target sites and limits its availability. Cu can be potentially toxic to the body and these proteins and enzymes pro-
tect our body from oxidative damage. Transition metals such as Cu regulate the redox reactions in our body and 
altered dynamics of their transporters/regulators can lead to disturbed metal ion homeostasis and redox balance. 
Elevated lipid peroxidation products, altered antioxidant enzyme levels and oxidized proteins have been reported 
in the epithelial lining fluid of the IPF patients29–33. It suggests oxidative stress plays important role in the patho-
genesis of IPF30 and accordingly, redox-modulatory therapy for IPF has been envisaged32.
Top significant proteins by PLS-DA modeling in our study also included several protease inhibitors such 
as SERPINA3, SERPING1 and ITIH2 (Supplementary Table 2 in Supplementary dataset). These proteins were 
also significant by FDR corrected t-test p values (<0.05). SERPING1 is a regulator of the classical complement 
pathway and as discussed above, points towards dysregulation of complement system in IPF. SERPINA3 regu-
lates fibrinolysis which is known to be altered in IPF34 and implicated in disease progression. Plasminogen was 
also found to be reduced in IPF patients compared to healthy controls in our study, which might indicate the 
consumption of plasmin and accordingly, elevated D-dimer concentration have been reported in IPF patients’ 
plasma35. Upon pathway analysis of all proteins quantified in our study complement and coagulation cascades 
were within the top 5 canonical pathways (B-H p-value <0.05). Taken together these observations indicate 
involvement of complement-coagulation system in development and/or progression of IPF. In network analysis 
of all proteins, proinflammatory cytokines, lipid metabolism and ERK1/2 pathways came up as hubs of the top 
network enriched with major modules being complement activation and coagulation cascade. Major lipid metab-
olism and transport pathways are known to be altered in lung diseases36. Although cholesterol is essential for 
lung function, excess of it was shown to interfere with normal surfactant function37. In line with these findings, 
agonists of cholesterol trafficking regulators, such as Liver X receptor reduces neutrophil recruitment and pro 
inflammatory responses38. Note that LXR/RXR activation was the top canonical pathway enriched in Ingenuity 
pathway analysis of all proteins. Moreover, in blood proteome of IPF patients ERK1/2 pathway and cytokine 
activity has been previously reported to be enriched26 lending support to our study.
One of the major aims of the current study was to find suitable predictive biomarkers which was performed by 
comparing FDR corrected p value of t-test (66 significant proteins) and proteins having VIP value of more than 
1 in PLS-DA (30 proteins). Twenty four proteins were common to both the methods (Supplementary Table 2 in 
Supplementary dataset). When the additional filter of fold change of more than 2 was employed, only HPR out 
of the 24 proteins remained significant. HPR was 2.2 times reduced in IPF patients. HPR, like haptoglobin is a 
hemoglobin binding protein which help protects from toxic effects of free heme on the body. In haptoglobin-null 
mouse model, hemolytic stress leads to kidney injury due to oxidative damage39. In haptoglobin and hemopexin 
double null mouse model, hemolytic stress causes inflammation of liver, cirrhosis and splenomegaly40. Subsequent 
kupffer cells activation leads to secretion of pro-inflammatory cytokines culminating in fibrosis40. Recall that 
hemopexin is also found to be significant by VIP in our study and is reduced in IPF patients. Our dataset hints 
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toward a similar mechanism of events in IPF, activation of complement leading to hemolysis and impairment of 
antioxidant function leading to inflammation and eventual fibrosis. This needs to be established by future mech-
anistic studies. HPR as a biomarker makes biological sense in IPF patients as oxidative stress related injury has 
been proposed as one of the mechanisms contributing to IPF progression. The mechanism of action of pirfeni-
done is now fully known, but it has been shown to work, at least partially, by regulating intracellular antioxidant 
functions thereby reducing oxidative stress in pulmonary fibrosis15. In a study of proteomics of BALF from IPF 
patients compared to controls, oxidative stress was found to be as one fo the enriched pathways by systems biol-
ogy approaches19. HPR has also been shown to separate bacterial pneumonia from non-bacterial pneumonia in 
a previous study41. One of the potential shortcomings of our study is non-inclusion of pneumonia patients which 
have been ruled out for IPF. It would be interesting and informative to measure HPR levels in other respiratory 
diseases of known causes. Further validation of HPR in larger independent cohorts is warranted in future stud-
ies. In Fig. 4, ROC curve of HPR can be seen together with the optimal cutoff at which 80% of sensitivity and 
selectivity could be achieved. Considering there are no known biomarkers in clinical practice, our study provides 
a single candidate found by overlap and statistical validation by two independent techniques. When we use the 
term biomarkers here, it means detection biomarkers which would help indicate to the clinician the need for fur-
ther clinical, radiological and histological testing in patients where no known causes (drug reaction, hazardous 
material exposure, systemic autoimmune diseases etc.) are apparent. It can further be validated in future studies 
as not only detection but also monitoring biomarkers where our working hypothesis is that treatment would lead 
to restoration, either full or partial, of HPR levels in IPF patients bringing them closer to healthy persons.
Our pilot study establishes HPR as a candidate biomarker of IPF and highlights dysregulated pathways from 
plasma proteome. Of note, our study has some limitations including modest number of IPF samples but  it pro-
vides impetus for future studies to validate our results in more numerous cohorts for IPF patients and other inter-
stitial lung diseases. In view of lack of highly specific antibodies against HPR, to the best of our knowledge, mass 
spectrometry based assays would be the way forward for future validation of candidate biomarkers.
In conclusion, proteomic signature of plasma can be used to identify candidate biomarkers of IPF which are 
significant by multiple statistical procedures. Some of these candidates, including C3 and SERPING3, are previ-
ously known to be dysregulated in blood proteome of IPF patients. LXR/RXR activation, complement activation 
and coagulation cascade were among the top pathways enriched in plasma proteome of IPF patients as revealed 
by pathway and network analysis of proteomics dataset. Our study reveals HPR as a candidate marker of IPF, 
which should be validated in future studies.
Materials and Methods
Patients, Ethics and study design. All IPF patients were recruited from FinnishIPF registry42, which is 
a national registry study. Healthy age-, sex- and smoking status matched control samples are from the hospital 
based Helsinki Biobank. The Ethics Committee of the Helsinki University Hospital, Helsinki, Finland (permit 
numbers 426–13–03–01–09 and HUS/359/2017), approved statements for the use of samples. The study was car-
ried out according to relevant guidelines and all patients gave written informed consent to participate in the study.
Plasma sample processing. The blood samples were collected in EDTA plasma tubes and they were centri-
fuged at 2000g for 10 minutes to isolate plasma at +4 °C. Samples were frozen at −80 °C until used for the study. 
Plasma samples were processed essentially as described previously43–45. Briefly, plasma samples were thawed and 
10 µL was used for depleting TOP 12 abundant proteins according to manufacturer’s instructions (Pierce, Thermo 
Fisher). Top 12 proteins depleted plasma was used for total protein estimation using BCA assay (Pierce, Thermo 
Fisher). Equal amount of protein from each sample was dried in separate tubes and dissolved in 35 µL of 50 mM 
Tris containing 6 M Urea (pH 7.8). After vortexing, dithiothreitol (DTT) was added to a final concentration of 
10 mM and shaken for 1 hour at RT. Subsequently, 40 mM iodoacetamide (IAA, final concentration) was added 
to the tubes and shaken for 1 hour. Further, 40 mM DTT (final concentration) was added to the tubes to quench 
any remaining IAA for 1 hour on shaking. Protein solution was diluted with 1:10 with 50 mM Tris buffer (pH 7.8) 
and in a ratio of trypsin: total protein, 1:50, trypsin (Trypsin Gold, Promega) was added. The samples tubes were 
incubated at 37 °C for 18 hours without shaking. Next morning, samples were cleaned with C18 spin columns 
(Pierce, Thermo Fisher) according to manufacturer’s instructions. Samples were dried and reconstituted in 0.1% 
formic acid containing 50 fmol of Hi3 peptide mixtures (Waters, MA, USA) per 4 µL. Rationale for addition of 
Hi3 as a spiked standard is described below.
UPLC-UDMSe. 500 ng peptides were injected to nano Acquity UPLC (Ultra Performance Liquid 
Chromatography) ‐ system (Waters Corporation, MA, USA). TRIZAIC nanoTile 85 μm × 100 mm HSS‐T3u 
wTRAP was used to separate peptide by liquid chromatography before mass spectrometer. Samples were loaded, 
trapped and washed for two minutes with 8.0 μL/min with 1% B. The analytical gradient used is as follows: 
0–1 min 1% B, at 2 min 5% B, at 65 min 30% B, at 78 min 50% B, at 80 min 85% B, at 83 min 85% B, at 84 min 1% 
B and at 90 min 1% B with 450 nL/min. Buffer A: 0.1% formic acid in water and Buffer B: 0.1% formic acid in 
acetonitrile.
Data independent acquisition using UDMSE mode was performed with Synapt G2‐S HDMS (Waters 
Corporation, MA, USA). The collected data range was 100–2000 m/z, scan time one‐second and ion-mobility 
spectroscopy (IMS) wave velocity was fixed at 650 m/s. Triplicate runs for each sample were acquired and further 
analysis was done with Progenesis QI for Proteomics – software (Nonlinear Dynamics, Newcastle, UK).
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Data analysis
Data analysis was performed as described previously43–45. Briefly, the raw files were imported to Progenesis 
QI for proteomics software (Nonlinear Dynamics, Newcastle, UK). Ion, 785.8426 m/z, corresponding to dou-
bly charged Glu1‐Fibrinopeptide B was used for lock mass correction. Default parameters were used for peak 
picking and chromatographic peak alignment. The software facilitated the peptide identification with Protein 
Lynx Global Server and label‐free quantification was according to Silva et al.46. The peptide identification was 
done against Uniprot human FASTA sequences (UniprotKB Release 2015_09, 20,205 sequence entries) with 
(CLPB_ECOLI (P63285)), ClpB protein sequence (Hi3 peptide mixture) inserted for label‐free quantification. 
Carbamidomethylation of cysteine as a fixed modification and oxidation of methionine as variable modification 
were used for database searching. Trypsin was used as digesting agent and two missed cleavage was allowed. 
Fragment and peptide error tolerances were set to auto and FDR to less than 1%. One or more ion fragments per 
peptide, three or more fragments per protein and one or more peptides per protein were required for ion match-
ing. The identified proteins were grouped together according to parsimony principle and also peptides unique to 
the protein are reported. Top 12 abundant proteins depleted were removed from further analysis.
Statistics. Scaling of the data, Hierarchical clustering, partial least square-discriminant analysis (PLS-DA) 
and receiver operating curve (ROC) analysis was performed by R-program based server MetaboAnalyst47,48. 
Individual normalized relative peptide intensities were used for pareto scaling of the data which were used for 
PLS-DA with all proteins. For PLS-DA, 10 fold cross validation was employed and permutation testing with 100 
permutations was also performed. The differential expression analysis was done in four distinct steps. Briefly, 1. 
t-test was performed on the Control vs IPF group individual normalized abundances values and 0.05 was taken 
as threshold for considering significantly different proteins. FDR corrected p-values were calculated according 
to the method of Benjamini-Hochberg correction of raw p-values. 2. These FDR corrected p value significant 
proteins were further filtered to include only proteins which differed between the groups by fold change of 2 or 
above to give us a list of proteins. 3. Partial least square-discriminant (PLS-DA) analysis was performed on all 
proteins quantified in our study and variable influence on projections (VIP) values of 1 or more were considered 
significant. 4. Proteins significant in step 2 (FDR corrected p-value <0.05, FC of 2 or more) and step 3 (VIP 
values of ≥1) were compared and overlapping proteins were considered significantly differentially expressed. 
Data were analyzed through the use of IPA49 (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/
ingenuitypathway-analysis).
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the 
PRIDE50 partner repository with the dataset identifier PXD010965 and 10.6019/PXD010965.
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